Dechra Pharmaceuticals

Dechra is an international specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide. Our key focus therapeutic areas are: • Endocrinology • Dermatology • Anaesthesia and analgesia • Ophthalmology • Cardiovascular disease • Equine locomotion • Food producing animal antimicrobials • And pet diets
Type
Public
HQ
Lostock Gralam, GB
Founded
1997
Size (employees)
1,308 (est)+52%
Website
dechra.com
Dechra Pharmaceuticals was founded in 1997 and is headquartered in Lostock Gralam, GB

Dechra Pharmaceuticals Office Locations

Dechra Pharmaceuticals has offices in Lostock Gralam, Hadnall, Skipton, Melbourne and in 6 other locations
Lostock Gralam, GB (HQ)
Cheshire Business Park Roundabout
Torino, IT
Via Agostino da Montefeltro
Barcelona, ES
202 Carrer de Balmes
Uldum, DK
9 Mekuvej
Leawood, US
525 7015 College Blvd
Melbourne, US
2571 W Eau Gallie Blvd
Skipton, GB
Snaygill Industrial Estate Keighley Rd
Hadnall, GB
Sansaw Business Park Hardwicke Stables

Dechra Pharmaceuticals Metrics

Dechra Pharmaceuticals Financial Metrics

Revenue (2016)

£247.6 m

Revenue growth (2015-16), %

22%

Gross profit

£132.4 m

Gross profit margin (2016), %

53%

Net income (2016)

£12.5 m

Market capitalization (22-Mar-2017)

£1.6 b

Closing share price (22-Mar-2017)

£16.8

Cash (30-Jun-2016)

£39.1 m
Dechra Pharmaceuticals's current market capitalization is £1.6 b.
Dechra Pharmaceuticals's revenue was reported to be £247.6 m in FY, 2016 which is a 21.7% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

£189.2 m£193.6 m£203.5 m£247.6 m

Revenue growth, %

2%5%22%

Cost of goods sold

£88.5 m£85.9 m£87.3 m£115.1 m

Gross profit

£100.7 m£107.7 m£116.1 m£132.4 m

Gross profit Margin, %

53%56%57%53%

Operating expense total

£82.4 m£82.7 m£90.2 m£112.9 m

Pre tax profit

£21.4 m£25.8 m£14.5 m

Net Income

£19.4 m£19.5 m£12.5 m
FY, 2014FY, 2015FY, 2016

Cash

£26.8 m£45.9 m£39.1 m

Accounts Receivable

£28.3 m£27.7 m£59.2 m

Current Assets

£86.3 m£108.6 m£162.5 m

PP&E

£18.3 m£18.2 m£37.9 m

Goodwill

£196.2 m£166.7 m£360.4 m

Total Assets

£300.8 m£293.5 m£560.8 m

Accounts Payable

£12.9 m£10.4 m£24.3 m

Current Liabilities

£35.7 m£44.1 m£66.3 m

Retained Earnings

£6.8 m£5.6 m(£2.6 m)

Total Equity

£204.8 m£194.5 m£274.6 m

Financial Leverage

1.5 x1.5 x2 x
FY, 2014FY, 2015FY, 2016

Cash From Operating Activities

£11.5 m£41 m£43.6 m

Cash From Financing Activities

(£92.1 m)(£14.8 m)£125.3 m

Income Taxes Paid

(£2 m)(£6.3 m)(£2 m)

Dechra Pharmaceuticals Market Value History

Dechra Pharmaceuticals Online Presence

Dechra Pharmaceuticals News

Dechra Pharmaceuticals Company Life

You may also be interested in